Goldenwell Biotech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GWLL research report →
Companywww.goldenwellbiotech.com
Goldenwell Biotech, Inc. , focuses on nutraceutical and dietary supplements business in the United States. The company is developing five products, including JI MAI—bovine cardiac vascular active peptide; cartilage peptide, a type II collagen peptide; and Double Proline AG 3D active collagen peptide, as well as DNA repair tablets and sugar master tablets.
- CEO
- Shuang Liu
- IPO
- 2022
- Employees
- 3
- HQ
- Hudson, OH, US
Price Chart
Valuation
- Market Cap
- $50.49M
- P/E
- -654.72
- P/S
- 809.89
- P/B
- -518.66
- EV/EBITDA
- -834.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.12%
- Op Margin
- -96.91%
- Net Margin
- -120.49%
- ROE
- 96.76%
- ROIC
- -33.37%
Growth & Income
- Revenue
- $139 · -94.06%
- Net Income
- $-131,498 · -12.49%
- EPS
- $-0.00 · -8.33%
- Op Income
- $-123,098
- FCF YoY
- -7.31%
Performance & Tape
- 52W High
- $10.00
- 52W Low
- $0.20
- 50D MA
- $0.94
- 200D MA
- $1.45
- Beta
- 4.85
- Avg Volume
- 214
Get TickerSpark's AI analysis on GWLL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GWLL Coverage
We haven't published any research on GWLL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GWLL Report →